5,457 Shares in Hologic, Inc. (NASDAQ:HOLX) Purchased by Cerity Partners LLC

Cerity Partners LLC acquired a new stake in shares of Hologic, Inc. (NASDAQ:HOLX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 5,457 shares of the medical equipment provider’s stock, valued at approximately $390,000.

A number of other hedge funds also recently added to or reduced their stakes in HOLX. Seelaus Asset Management LLC raised its stake in shares of Hologic by 16.2% during the fourth quarter. Seelaus Asset Management LLC now owns 3,485 shares of the medical equipment provider’s stock worth $249,000 after purchasing an additional 485 shares during the last quarter. Impax Asset Management Group plc lifted its stake in shares of Hologic by 32.8% in the 4th quarter. Impax Asset Management Group plc now owns 15,771 shares of the medical equipment provider’s stock worth $1,127,000 after acquiring an additional 3,895 shares during the period. Sequoia Financial Advisors LLC boosted its holdings in shares of Hologic by 22.0% in the fourth quarter. Sequoia Financial Advisors LLC now owns 6,598 shares of the medical equipment provider’s stock valued at $471,000 after acquiring an additional 1,191 shares in the last quarter. International Assets Investment Management LLC acquired a new position in shares of Hologic during the fourth quarter worth about $950,000. Finally, Bleakley Financial Group LLC raised its holdings in Hologic by 6.4% during the fourth quarter. Bleakley Financial Group LLC now owns 4,576 shares of the medical equipment provider’s stock worth $327,000 after purchasing an additional 274 shares in the last quarter. 94.73% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Hologic

In other Hologic news, CFO Karleen Marie Oberton sold 14,940 shares of the firm’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $75.00, for a total transaction of $1,120,500.00. Following the sale, the chief financial officer now directly owns 103,916 shares of the company’s stock, valued at approximately $7,793,700. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Scott T. Garrett sold 16,441 shares of Hologic stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total value of $1,241,295.50. Following the completion of the sale, the director now owns 48,611 shares of the company’s stock, valued at $3,670,130.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CFO Karleen Marie Oberton sold 14,940 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $75.00, for a total value of $1,120,500.00. Following the transaction, the chief financial officer now owns 103,916 shares in the company, valued at $7,793,700. The disclosure for this sale can be found here. In the last quarter, insiders sold 32,846 shares of company stock valued at $2,473,443. 1.75% of the stock is owned by insiders.

Hologic Stock Up 0.4 %

HOLX stock opened at $75.98 on Friday. The company has a debt-to-equity ratio of 0.55, a current ratio of 3.89 and a quick ratio of 3.18. The company’s 50 day simple moving average is $76.03 and its 200-day simple moving average is $72.78. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $87.88. The firm has a market capitalization of $17.83 billion, a PE ratio of 36.01, a P/E/G ratio of 2.60 and a beta of 1.00.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 earnings per share for the quarter, topping the consensus estimate of $0.95 by $0.03. Hologic had a return on equity of 18.91% and a net margin of 12.98%. The company had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $989.32 million. During the same quarter last year, the business posted $1.07 earnings per share. Hologic’s revenue was down 5.7% compared to the same quarter last year. Equities analysts expect that Hologic, Inc. will post 4.01 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on the company. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. Needham & Company LLC reaffirmed a “buy” rating and set a $90.00 price objective on shares of Hologic in a report on Wednesday, April 10th. UBS Group raised their price objective on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a research note on Friday, February 2nd. Raymond James upped their target price on shares of Hologic from $85.00 to $88.00 and gave the stock an “outperform” rating in a research report on Friday, February 2nd. Finally, Evercore ISI lifted their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a research report on Thursday, April 4th. Six research analysts have rated the stock with a hold rating and four have given a buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $87.00.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.